



The World Health Organization grants the name *ecubectedin* to PharmaMar's anti-tumor compound PM14

Madrid, September 13th, 2021. –PharmaMar (MSE:PHM) has announced today that the World Health Organization (WHO) has confirmed the International Nonproprietary Name (INN) of its investigational anti-tumor compound PM14 as ecubectedin.

The WHO has published a list of recommended INNs on its website, including this new name for PharmaMar's active ingredient, which means that it can now be used officially.

Ecubectedin is currently in Phase I-II clinical development, both as a single agent and in combination with other drugs for the treatment of solid tumors. The four ongoing clinical trials with this compound are being conducted in 12 hospitals in Spain, France, the United Kingdom and the United States.

Ecubectedin is a compound that acts by specifically inhibiting RNA synthesis and active transcription of protein-coding genes.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and now commercializes Yondelis[®] in Europe by itself, as well as Zepzelca[®] (lurbinectedin), in the US; and Aplidin[®] (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and PM14. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar also wholly owns other companies: GENOMICA, a molecular diagnostics



company; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

María Marín de la Plaza – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com